Knight Therapeutics Inc. Continues to Execute Its Innovative Pharmaceutical Product Sourcing Strategy
MONTREAL, QUEBEC–(Marketwired – Oct. 28, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has invested CAD$30 million into Teralys Capital Innovation Fund LP (“Teralys Fund”). This investment in another proven successful life science fund complements Knight's USD$13 million investment in Sectoral and EUR19.5 million investment in […]
Knight Therapeutics Inc. Expands Its Innovative Pharmaceutical Product Sourcing Strategy
MONTREAL, QUEBEC–(Marketwired – Oct. 2, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has expanded its innovative pharmaceutical product sourcing strategy for the Canadian market. This strategy is based on the conviction that with targeted incentives, an investment in time proven life science funds will generate […]
Knight Therapeutics Inc. Acquires Orphan Canada Inc. and Expands Business Development Capacity
MONTREAL, QUEBEC–(Marketwired – Sept. 2, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an asset purchase agreement with Orphan Canada Inc. (“Orphan”) related to the Canadian rights for ATryn® and PHOTOFRIN® (porfimer sodium), two innovative pharmaceutical products approved for sale in multiple jurisdictions. […]
Knight Expands Team
MONTREAL, QUEBEC–(Marketwired – Aug. 26, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today (1) the appointment of Amal Khouri to the position of Vice President of Business Development and (2) the appointment of Sylvie Tendler to Knight's Board of Directors. “Both Amal and Sylvie are proven pharmaceutical executives and expand our capacity to secure […]
Knight Reports Second Quarter 2014 Results
MONTREAL, QUEBEC–(Marketwired – Aug. 14, 2014) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD) today reported its financial results for the quarter ended June 30, 2014. 2nd Quarter 2014 Highlights During the second quarter of 2014: On April 10, 2014, Knight completed a private placement of Additional Special Warrants for aggregate proceeds of $180,075,000. On April 17, […]
Knight Therapeutics Inc. Hires Advisor to Sell Its Priority Review Voucher
MONTREAL, CANADA–(Marketwired – Aug. 12, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into an arrangement with a global investment banking firm to sell its neglected tropical disease Priority Review Voucher (“PRV”). The arrangement is effective August 18, 2014. Developed by the U.S. FDA […]
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement to Support the Acquisition of Apicore
MONTREAL, CANADA–(Marketwired – July 3, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement to support the acquisition of two newly formed holding companies of which Apicore LLC and Apicore US LLC (collectively, “Apicore”) will be wholly owned operating subsidiaries. […]
Knight Therapeutics Inc. Invests in Sectoral Asset Management Inc. for Preferred Access to Canadian Product Rights
MONTREAL, QUEBEC–(Marketwired – June 26, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a letter of agreement with Sectoral Asset Management Inc. (“Sectoral”) to invest USD$13 million into its New Emerging Medical Opportunities Funds II, Ltd. (“NEMO II”). In exchange for Knight's investment […]
Knight Therapeutics Inc. and Origin Biomed Inc. Sign Secured Debt Financing Agreement
MONTREAL, CANADA–(Marketwired – June 25, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured debt agreement with privately-held Origin Biomed Inc. (“Origin”), a company dedicated to the worldwide commercialization of the Neuragen® and Bionica brands. The $850,000 Canadian secured loan issued by […]
Knight Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto
MONTREAL, CANADA–(Marketwired – June 17, 2014) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday June 18, 2014 at 11:30 am ET at the […]
